Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mark Richards

Showing results (11-20 of 456) with videos related to

Pageof 46
Sort By:
Cardiac Failure Review|August 9, 2017
Biomarkers in Acute Heart Failure - Cardiac And KidneyA Mark Richards
Heart (British Cardiac Society)|July 20, 2007
Variability of NT-proBNP levels in heart failure: implications for clinical applicationA Mark Richards
JACC. Heart Failure|August 15, 2016
The Relationship of Plasma NT-proBNP to Age and Outcomes in Heart FailureA Mark Richards
Clinical Chemistry|April 16, 2025
Cardiac Biomarkers in Pulmonary Embolism: Revealing or Redundant?A Mark Richards
European Journal of Heart Failure|May 16, 2023
Plasma markers to risk stratify for heart failure in atrial fibrillationA Mark Richards
Canadian Journal of Physiology and Pharmacology|August 5, 2011
Tailored therapy for heart failure: neurohormonesA Mark Richards
Evidence-Based Medicine|August 7, 2010
B-type natriuretic peptide-guided therapy for chronic heart failure reduces all-cause mortality compared with usual care but does not affect all-cause hospitalisation or survival free of hospitalisationA Mark Richards
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Natriuretic peptides: update on Peptide release, bioactivity, and clinical useA Mark Richards
Nature Reviews. Cardiology|October 17, 2018
Can heart failure cause cancer?A Mark Richards
Journal of the American College of Cardiology|September 13, 2008
Serial measurements of plasma B-type natriuretic peptides: what do they tell us?A Mark Richards
Pageof 46

Showing results (11-20 of 456) with videos related to

Sort By:
Pageof 46
Cardiac Failure Review|August 9, 2017
Biomarkers in Acute Heart Failure - Cardiac And KidneyA Mark Richards
Heart (British Cardiac Society)|July 20, 2007
Variability of NT-proBNP levels in heart failure: implications for clinical applicationA Mark Richards
JACC. Heart Failure|August 15, 2016
The Relationship of Plasma NT-proBNP to Age and Outcomes in Heart FailureA Mark Richards
Clinical Chemistry|April 16, 2025
Cardiac Biomarkers in Pulmonary Embolism: Revealing or Redundant?A Mark Richards
European Journal of Heart Failure|May 16, 2023
Plasma markers to risk stratify for heart failure in atrial fibrillationA Mark Richards
Canadian Journal of Physiology and Pharmacology|August 5, 2011
Tailored therapy for heart failure: neurohormonesA Mark Richards
Evidence-Based Medicine|August 7, 2010
B-type natriuretic peptide-guided therapy for chronic heart failure reduces all-cause mortality compared with usual care but does not affect all-cause hospitalisation or survival free of hospitalisationA Mark Richards
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Natriuretic peptides: update on Peptide release, bioactivity, and clinical useA Mark Richards
Nature Reviews. Cardiology|October 17, 2018
Can heart failure cause cancer?A Mark Richards
Journal of the American College of Cardiology|September 13, 2008
Serial measurements of plasma B-type natriuretic peptides: what do they tell us?A Mark Richards
Pageof 46